No Data
No Data
Shapuaisi Pharmaceutical Gets China Approval for Eye Drops Clinical Trial
Zhejiang Shapuaisi Pharmaceutical (603168.SH): Azithromycin eye drops approved for clinical trials.
Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced that the company's azithromycin eye drops have obtained approval and signed by the State Food and Drug Administration...
Zhejiang Shapuaisi PharmaceuticalLtd (SHSE:603168) Shareholders Are up 16% This Past Week, but Still in the Red Over the Last Year
Zhejiang Shapuaisi Pharmaceutical Enrolls First Subject in Phase 3 Trial for Presbyopia Eye Drops
Zhejiang Shapuaisi Pharmaceutical (603168.SH): The Phase III clinical trial of Mao Guo Yun Xiang Alkaline Hydrochloride Eye Drops has completed the enrollment of the first subject.
Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced that the company has organized and conducted the Phase III clinical trial of tropicamide hydrochloride eye drops.
Zhejiang Shapuaisi Pharmaceutical (603168.SH): obtained the 'Pharmaceutical Registration Certificate' for Diquafosol Sodium Eye Drops.
On September 3, Guilonghui announced that Zhejiang Shapuaisi Pharmaceutical (603168.SH) has received the Drug Registration Certificate issued by the National Medical Products Administration. The approved diquafosol sodium eye drops are single-dose eye drops without preservatives, suitable for dry eye patients diagnosed with corneal epithelial damage associated with tear abnormalities.
No Data
No Data